mRNA-based HIV-1 vaccines

S Ahmed, A Herschhorn - Clinical microbiology reviews, 2024 - journals.asm.org
The success of the Severe Acute Respiratory Syndrome Coronavirus 2 mRNA vaccines to
lessen/prevent severe COVID-19 opened new opportunities to develop RNA vaccines to …

[HTML][HTML] Protein and glycan mimicry in HIV vaccine design

GE Seabright, KJ Doores, DR Burton… - Journal of molecular …, 2019 - Elsevier
Antigenic mimicry is a fundamental tenet of structure-based vaccinology. Vaccine strategies
for the human immunodeficiency virus type 1 (HIV-1) focus on the mimicry of its envelope …

Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA

AK Blakney, PF McKay, BI Yus, Y Aldon, RJ Shattock - Gene therapy, 2019 - nature.com
Self-amplifying RNA (saRNA) is a promising biotherapeutic tool that has been used as a
vaccine against both infectious diseases and cancer. saRNA has been shown to induce …

[HTML][HTML] Human immunoglobulin repertoire analysis guides design of vaccine priming immunogens targeting HIV V2-apex broadly neutralizing antibody precursors

JR Willis, ZT Berndsen, KM Ma, JM Steichen… - Immunity, 2022 - cell.com
Broadly neutralizing antibodies (bnAbs) to the HIV envelope (Env) V2-apex region are
important leads for HIV vaccine design. Most V2-apex bnAbs engage Env with an …

Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates

KO Saunders, N Pardi, R Parks, S Santra, Z Mu… - npj Vaccines, 2021 - nature.com
The development of an effective AIDS vaccine remains a challenge. Nucleoside-modified
mRNAs formulated in lipid nanoparticles (mRNA-LNP) have proved to be a potent mode of …

Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence

K Sliepen, BW Han, I Bontjer, P Mooij, F Garces… - Nature …, 2019 - nature.com
Stabilized HIV-1 envelope glycoproteins (Env) that resemble the native Env are utilized in
vaccination strategies aimed at inducing broadly neutralizing antibodies (bNAbs). To limit …

Infection and transmission of SARS‐CoV‐2 depend on heparan sulfate proteoglycans

M Bermejo‐Jambrina, J Eder, TM Kaptein… - The EMBO …, 2021 - embopress.org
The current pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS‐
CoV‐2) and outbreaks of new variants highlight the need for preventive treatments. Here, we …

Structure‐guided envelope trimer design in HIV‐1 vaccine development: a narrative review

R Derking, RW Sanders - Journal of the International AIDS …, 2021 - Wiley Online Library
Introduction The development of a human immunodeficiency virus 1 (HIV‐1) vaccine
remains a formidable challenge. An effective vaccine likely requires the induction of broadly …

CoPoP liposomes displaying stabilized clade C HIV-1 Env elicit tier 2 multiclade neutralization in rabbits

A Koornneef, K Vanshylla, G Hardenberg… - Nature …, 2024 - nature.com
One of the strategies towards an effective HIV-1 vaccine is to elicit broadly neutralizing
antibody responses that target the high HIV-1 Env diversity. Here, we present an HIV-1 …

Impact of stabilizing mutations on the antigenic profile and glycosylation of membrane-expressed HIV-1 envelope glycoprotein

T Tong, A D'Addabbo, J Xu, H Chawla… - PLoS …, 2023 - journals.plos.org
Recent HIV-1 vaccine development has centered on “near native” soluble envelope
glycoprotein (Env) trimers that are artificially stabilized laterally (between protomers) and …